<DOC>
	<DOCNO>NCT02133482</DOCNO>
	<brief_summary>The primary objective trial investigate safety tolerability BI 639667 healthy male subject follow oral administration single rise dos . Secondary objective exploration pharmacokinetics ( PK ) include dose proportionality well investigation linearity pharmacodynamics ( PD ) BI 639667 single dose assessment PK/PD relationship .</brief_summary>
	<brief_title>Safety , Tolerability , Pharmacokinetics Pharmacodynamics Single Rising Oral Doses BI 639667</brief_title>
	<detailed_description />
	<mesh_term>Pharmaceutical Solutions</mesh_term>
	<criteria>Inclusion criterion : 1 . Healthy male subject 2. age 18 50 year 3. body mass index ( BMI ) 18.5 29.9 kg/m2 Exclusion criterion : 1 . Any finding medical examination ( include BP , pulse rate ( PR ) ECG ) deviate normal judge clinically relevant investigator 2 . Repeated measurement systolic blood pressure great 140 mmHg , diastolic blood pressure great 90 mmHg , pulse rate outside range 50 90 mmHg screen 3 . Any laboratory value outside reference range investigator considers clinical relevance 4 . Any evidence concomitant disease judge clinically relevant investigator 5 . Gastrointestinal , hepatic , renal , respiratory , cardiovascular , metabolic , immunological hormonal disorder 6 . Surgery gastrointestinal tract could interfere kinetics trial medication ( except appendectomy simple hernia repair ) 7 . Diseases central nervous system ( epilepsy ) , neurological disorder psychiatric disorder</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>July 2014</verification_date>
</DOC>